Devices, systems, and methods are provided for providing artificial intelligence assisted home therapy settings for a medical apparatus. The devices, system, and methods are related to, though not exclusively, to a system and method of providing artificial intelligence assisted home therapy settings for dialysis.
Biomedical devices and other therapeutic apparatus improve human lives by providing therapeutic treatment, which may for example treat diseases or otherwise improve the functioning of the human body. Certain biomedical devices are entering home use but can require relatively complex or specific control settings. The control settings are needed for proper function and usefulness of a medical treatment such as for hemodialysis. For example, in-center hemodialysis is often administered and monitored by trained, in-center clinicians. However, a nephrologist may prescribe home treatment of hemodialysis to remove toxins such as urea from the blood. In setting up home hemodialysis, the patient and a primary care partner can be trained to perform dialysis safely, and to handle problems in the event of adverse conditions during the session. The in-center training might take several weeks to several months. Apart from training, the patient and caretaker can be provided with material relevant to the medication, safety measures, proper usage, sanitation, installation, and access to 24-hour support from care centers. However, the resulting cognitive load on the patient and caretaker can be large. Even after many hours of training, some patients and caretakers may be unable to properly comprehend and adjust control settings as may be required. Moreover, even trained clinicians in a clinical environment may be overwhelmed or fail to implement or recognize a problem. These issues could result in inconsistencies or sub-optimal outcomes in the dialysis adequacy and may pose health and safety risks to the patient.
The known systems and methods fail to provide a suitable home therapy system that assists and/or automates the process of setting control parameters. The known systems and methods fail to ameliorate a steep learning curve and cognitive load on home therapy systems and methods imposed upon caregivers and patients receiving home dialysis. The known systems and methods fail to suggest and/or automate treatment parameters such as the blood flow rate/profiles with visual representation rates during hemodialysis delivery and blood return for home therapy.
Hence, there is a need for an electronic system that can advise patients during in-home treatments. There is a need for systems and methods that can automate or provide recommendations that can be implemented by a user whether in a clinical or home setting. There is a related need to provide analysis of patient records and other historical data to assist in setting parameters for a therapy. There is a further need for systems and methods for providing recommendations for blood flow rate and similar treatment parameters influencing a medical therapy such as dialysis. There is a need for a machine implemented system and method for recommending and/or setting parameters used in dialysis. There is a need for a system and method suitable for dialysis home therapy. There is a related need for recommending and automating a blood flow rate using a therapy or smart engine with artificial intelligence. The need relates to assisting patients, caregivers, clinicians, and doctors administering treatment themselves in a home or clinical setting. The need includes aiding medical professionals who are experienced, but who can benefit from the insights of a machine learning system and method. The need extends a network connected medical device that receive and send data. The need still further includes a medical device that can receive and send algorithms, recommendations, or instructions of any type.
The systems and methods can help reduce a steep learning curve and cognitive load of performing therapy whether in a clinical or home setting by any type of user. The system and method disclosed herein can help both nurses and patients who are participating in-home dialysis, and also can help physicians and others in-clinic who are desirous of electronic assistance in sorting through the large volume of records available.
The first aspect relates to a medical device. In any embodiment, the medical device can include: a therapeutic subsystem to deliver a medical therapy, including one or more sensors to monitor a biometric health factor; a user interface; a controller, including a processor and a memory; therapy software including instructions encoded within the memory to instruct the processor to receive a prescribed therapy, to receive a therapeutic setting recommendation, and to display the therapeutic setting recommendation to an operator via the user interface; a network interface, and instructions to receive, via the network interface, a prepared artificial intelligence (AI) model from a cloud service; and an AI circuit having execution hardware including at least one logic gate, and further including instructions to instruct the execution hardware to execute the prepared AI model to recommend a therapy setting for the therapeutic subsystem, wherein the circuit is incorporated into the prepared AI model data from the sensor.
In any embodiment, the execution hardware can include the processor.
In any embodiment, the device can be selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.
In any embodiment, the device can be a dialysis machine.
In any embodiment, the prepared AI model can incorporate input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.
In any embodiment, the therapy setting recommendation can include a blood flow rate recommendation.
In any embodiment, the therapy software instructions can further automatically select a recommended blood flow rate.
In any embodiment, the therapy software instructions can further detect a changed blood flow rate during therapy, and the AI circuit can further predict a recommendation according to the changed blood flow rate.
In any embodiment, the sensor can detect an adverse condition, and the AI circuit can recommend a blood flow rate according to the adverse condition.
In any embodiment, the adverse condition can include low patient blood pressure.
In any embodiment, the therapy software instructions can further save one or more blood flow rate profiles for a patient.
In any embodiment, the therapeutic setting recommendation can be selected from blood flow rate, sodium profile, and ultrafiltration rate profile.
In any embodiment, the user interface can include a control to request a therapeutic setting recommendation.
In any embodiment, the user interface can include one or more controls to automatically accept or reject recommended therapeutic settings.
In any embodiment, the therapy software instructions can further download the treatment parameters from a cloud service.
In any embodiment, the AI circuit can provide a high clearance prediction.
In any embodiment, the AI circuit can further concurrently provide a plurality of recommended therapeutic settings.
In any embodiment, the AI circuit can provide an AI model selected from the group consisting of linear regression, logistic regression, linear discriminant analysis, decision tree, naïve Bayes, k-nearest neighbors, learning vector quantization, support vector machine, random forest, neural network, convolutional neural network, and deep neural network.
In any embodiment, a system can be provided, including the medical device of any previous embodiment, and further including a cloud service, the cloud service including a hardware platform including a processor and a memory, and instructions encoded within the memory to instruct the processor to receive a plurality of historical patient inputs and build the prepared model from the plurality of historical patient inputs.
In any embodiment, a system can be provided, wherein the prepared model can be a patient-specific model.
In any embodiment, a system can be provided, wherein the prepared model can be specific to a class of patients.
The features disclosed as being part of the first aspect can be in the first aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the first aspect can be in a second or third aspect described below, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.
The second aspect relates to a method of providing therapy recommendations for a medical device. In any embodiment, the method can include: receiving a prescribed therapy regimen for a patient; receiving a patient profile for the patient; operating an artificial neural network (ANN) to compute a recommended therapy setting according to a regression model, wherein the prescribed therapy regimen and the patient profile are inputs to the regression model; and displaying the recommended therapy in a human-readable format.
In any embodiment, the method can further include executing on hardware that includes a processor.
In any embodiment, the device can be selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.
In any embodiment, the device can be a dialysis machine.
In any embodiment, the ANN can receive an input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.
In any embodiment, the recommended therapy setting can include a blood flow rate recommendation.
In any embodiment, the method can further include automatically selecting a recommended blood flow rate.
In any embodiment, the method can further include detecting a changed blood flow rate during therapy, and the ANN can further predict a recommendation according to the changed blood flow rate.
In any embodiment, the method can further include detecting an adverse condition, and the ANN can recommend a blood flow rate according to the adverse condition.
In any embodiment, the adverse condition can include low patient blood pressure.
In any embodiment, the method can further include saving one or more blood flow rate profiles for a patient.
In any embodiment, the method can further include selecting the recommended therapy setting from blood flow rate, sodium profile, and ultrafiltration rate profile.
In any embodiment, the method can further include requesting a therapeutic setting recommendation.
In any embodiment, the method can further include automatically accepting or rejecting recommended therapeutic settings.
In any embodiment, the method can further include downloading the historical treatment parameters from a cloud service.
In any embodiment, the ANN can provide a high clearance prediction.
In any embodiment, the ANN can further concurrently provide a plurality of recommended therapeutic settings.
The features disclosed as being part of the second aspect can be in the second aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the second aspect can be in the first or third aspect described below, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.
The third aspect relates to one or more tangible, non-transitory computer-readable media. In any embodiment, the computer-readable media can have stored thereon executable instructions to: receive a therapy prescription for a patient; receive a patient profile for the patient; run, in an ANN, a regression model having as inputs the therapy prescription and the patient profile, and as an output a recommended therapy setting for a medical device; and operate a user interface to display the recommended therapy setting.
In any embodiment, the instructions can be to run on hardware including a processor.
In any embodiment, the instructions can be to operate a device selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.
In any embodiment, the instructions can be to operate a dialysis machine.
In any embodiment, the ANN can receive an input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.
In any embodiment, the recommended therapy setting can include a blood flow rate recommendation.
In any embodiment, the instructions can automatically select a recommended blood flow rate.
In any embodiment, the instructions can be to further detect a changed blood flow rate during therapy, and the ANN can further predict a recommendation according to the changed blood flow rate.
In any embodiment, the instructions can be to further detect an adverse condition, and the ANN can recommend a blood flow rate according to the adverse condition.
In any embodiment, the adverse condition can include low patient blood pressure.
In any embodiment, the instructions can be to further save one or more blood flow rate profiles for a patient.
In any embodiment, the recommended therapy setting can be selected from blood flow rate, sodium profile, and ultrafiltration rate profile.
In any embodiment, the user interface can include a control to request a therapeutic setting recommendation.
In any embodiment, the user interface can include one or more controls to automatically accept or reject recommended therapeutic settings.
In any embodiment, the instructions can be further to download the historical treatment parameters from a cloud service.
In any embodiment, the ANN can provide a high clearance prediction.
In any embodiment, the ANN can further concurrently provide a plurality of recommended therapeutic settings.
The features disclosed as being part of the third aspect can be in the third aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the third aspect can be in the first or second aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.
Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art.
The articles “a” and “an” are used to refer to one to over one (i.e., to at least one) of the grammatical object of the article. For example, “an element” means one element or over one element.
The term “biomedical device” refers to any device that provides therapy, monitoring, or telemetry for a biological entity, and most particularly, for a human. Biomedical devices can passively monitor a human patient, or they can actively administer a therapeutic service.
The term “biometric s” can be any measurement obtained from a living organism. In general, the measurement is indicative of a health status of the living organism such as analytical data obtained from various lab testing and history data or from any sensor that can sense a measurand of any type, e.g., blood pressure, body weight, temperature, etc. One of ordinary skill will appreciate that many biometric parameters can be indicated of a health status and are all contemplated.
The term “blood flow rate” refers to the rate at which blood is extracted and filtered during hemodialysis.
The term “blood flow rate profile” refers to a time series profile that defines blood flow rates at different points of therapy.
The term “blood pressure” refers to a measure of the systolic and diastolic blood pressure.
The term “circuit” refers to any electronic analog, digital, or mixed-signal electronic network. In the case of digital or mixed-signal networks, the circuit can also include instructions or other inputs that are used to program the circuit.
The term “cloud service” refers to any collection of one or more machines, connected via a network such as the internet, that provides a non-local service.
The term “continuous positive airway pressure machine” refers to a medical device that provides forced air to a patient while sleeping to mitigate sleep apnea.
The term “controller” refers to a programmable circuit, which can include instructions to program the circuit, that controls a device.
The term “convolutional neural network” refers to a form of neural network that uses mathematical convolution to define the relationship between neurons.
The term “decision tree” refers to a branching model, with yes/no (or similar) decisions at each branch.
The term “deep neural network” refers to a neural network that generally includes an input layer, one or more intermediate hidden layers, and an output layer, in which each neuron of each layer is linked to each neuron of the next layer.
The term “dialysis machine” refers to a medical device that provides in-home or in-clinic hemodialysis.
The term “dialyzer permeability” refers to the permeability of a hollow fiber dialyzer bundle.
The term “dialyzer type” refers to one of several types of dialyzers, such as coil, parallel plate, hollow fiber, or ultrafiltration.
The term “execution hardware” refers to programmable hardware to read and act on the instructions of a computer program.
The term “external neural stimulator” refers to an electrical device to stimulate neurons.
The term “high clearance prediction” refers to a predicted condition to provide high dialysis clearance.
The term “human-readable format” refers to any format that is readily perceptible and understandable by a human.
The term “instructions” refers to machine-readable data that cause a processor to execute an algorithm. In the case of a microprocessor or microcontroller, the instructions can be a series of operation codes that, in a particular sequence, cause the processor to execute a desired algorithm. In the case of a field-programmable gate array (FPGA) or application-specific integrated circuit (ASIC), the instructions can be written in a hardware description language that is used to configure the circuit to carry out the algorithm.
The term “insulin pump” refers to a medical device that injects insulin into a patient.
The term “interface” refers to any combination of hardware, software, and/or firmware that enables one object to communicatively couple to another object.
The term “intravenous fluid device” refers to a device that injects fluid into a vein.
The term “k-nearest neighbors” refers to a model that makes predictions by mapping an input data set into an n-dimensional space, and identifying, for each node of interest, the k nodes that are nearest to a point in the space.
The term “learning vector quantization” refers to an evolution of k-nearest neighbors that employs a neural network.
The term “linear discriminant analysis” refers to a subclass of logistic regression that can be used when two or more classes can exist in the output.
The term “linear regression” refers to a statistical model that fits data to a line.
The term “logic gate” refers to an electronic circuit that receives one or more logical inputs, and provides at least one logical output as a function such as AND, OR, XOR, NAND, NOR, XNOR, delay, unity, or selection.
The term “logistic regression” refers to a statistical model that fits data to a logarithm, and is able to predict binary results.
The term “medical device” refers to an electronic device that provides at least one medical function.
The term “memory” refers to any electronic medium capable of storing encoded data.
The term “naïve Bayes” refers to a model that can predict a conditional probability according to a Bayesian calculation.
The term “neural network” refers to a form of artificial intelligence, not limited to a single algorithm, in which artificial “neurons” are connected in a network.
The term “operator” refers to a human who operates a device.
The term “patient access type” refers to the type of access to the patient, commonly one of fistula, graft, or catheter.
The term “patient condition” refers to any measure of patient health or status.
The term “patient profile” refers to a profile of blood flow rate across time, specific to a patient.
The term “processor” refers to any programmable or configurable logic circuit, which can be configured to execute a desired algorithm. A processor can provide a generalized instruction set, such as in the case of a microprocessor or microcontroller or can be configured in hardware as in the case of an application-specific integrated circuit (FPGA). In some cases, processors can be emulated and/or virtualized. For example, virtualization technology can provide a virtual processor running under a hypervisor, or other kind of virtualization layer, in which case the “processor” can include the emulation layer, as well as the physical processor that ultimately executes the instructions.
The term “random decision forest” refers to a form of decision tree, where multiple samples are processed by decision trees, and the results are aggregated.
The term “sodium profile” refers to the sodium concentration of dialysis fluid.
The term “software” refers to any sequence of instructions to instruct a programmable hardware to carry out an algorithm.
The term “support vector machine” refers to a model that employs a hyperplane line that separates data input nodes with different values.
The term “therapeutic subsystem” refers to a portion of a medical apparatus that administers therapy or treatment to a patient.
The term “therapy” refers to a medical procedure or regimen delivered to a patient.
The term “therapy method” refers to the method by which a therapy is delivered to the patient.
The term “therapy regimen” refers to the prescribed parameters, length, and methods of a treatment.
The term “therapy software” refers to software that controls administration and/or monitoring of therapy.
The term “ultrafiltration” refers to a form of hemodialysis in which excess fluid, such as water, is removed from the blood (in addition to removing toxins).
The term “ultrafiltration rate profile” refers to a profile, over time, of the rate at which ultrafiltration is performed during hemodialysis.
Medical Device Ecosystem
Patient 104 operates hemodialysis machine 108, which includes a graphical user interface (GUI) 112. GUI 112 permits patient 104 to interact with hemodialysis machine 108, and to provide inputs and view outputs. For example, GUI 112 can include a flow rate profile display, which could optionally include flow rate points. In some cases, GUI 112 can include a touch-sensitive display, so that patient 104 can directly interact with GUI 112, via the display.
Hemodialysis machine 108 can include various sensors that provide feedback to monitor the success and safety of the dialysis operation. For example, a real-time blood pressure monitoring circuit (RT BP Mon.) 114 can be provided, so that the patient's blood pressure can be monitored in real-time, or near real-time, and so that the system can detect whether the patient's blood pressure drops dangerously low.
Ecosystem 100 can also include a home gateway 120, which connects to various devices that can help provide useful inputs to hemodialysis machine 108. For example, a smart scale 116 could be used to measure the patient's dry weight, and/or the patient's weight after dialysis. Home blood pressure monitor 118 could be used to periodically check the blood pressure of patient 104, and to keep track of blood pressure trends. In some illustrative embodiments, hemodialysis machine 108, smart scale 116, and/or home blood pressure monitor 118 can communicatively couple to home gateway 120, such as via a wired or wireless network. Home gateway 120 can act as a gateway between the home environment and internet 124, which provides a wider and uncontrolled network.
The home gateway 120 can provide for communication between the home gateway 120 and a cloud data service 132. The cloud data service 132 can have various software modules to connect to the home gateway 120. Notably, the cloud data service 132 can establish a data communication channel with the home gateway 120 through a TCP/IP protocol or other suitable process, where a terminal is connected to the home gateway 120. The home gateway 120 software can send a first software message to the cloud data service 132 through the data communication channel so that the home gateway 120 establishes connection with cloud data service 132. One of ordinary will understand that other suitable connection methods, steps, and protocols can be implemented to establish such connection with an external cloud server. The cloud data service 132 can communicatively couple to home gateway 120 via internet 124 and can provide services to patient 104. For example, cloud data service 132 can provide a pre-trained AI model to hemodialysis machine 108, which can enable an artificial intelligence circuit on hemodialysis machine 108 to provide treatment parameter suggestions, such as a suggested flow rate or a flow rate profile. In some cases, clinic 128 can also connect to cloud data service 132 via internet 124, or via an intranet or other internal network. Clinic 128 can provide data such as electronic health records, a treatment prescription, and other inputs as described herein to cloud data service 132. Cloud data service 132 can then use those data to build the pre-trained AI model for use by hemodialysis machine 108. In some cases, the pre-trained AI model can be specific to patient 104, rather than a general model that can be used by many patients. In other embodiments, a general model that is applicable to a class or group of patients could also be provided.
Medical Treatment Ecosystem
In this example, within the clinic there is an enterprise gateway 220, which provides connectivity between various devices. Similar to
Medical Device
Medical device 300 includes a user interface 304, a therapeutic subsystem 308, a hardware platform 312, therapy software 316, an AI engine 320, and a recommendation engine 324. These are provided by way of illustrative and nonlimiting example. One of ordinary will understand that not all elements need be present in each embodiment, and some embodiments can include other elements. Furthermore, while these elements are shown as separate blocks, this does not necessarily imply that they are required to be provided as physically separate devices, or on separate hardware. The recommendation engine 324 can be provided may be a server, cloud service, or the like.
User interface 304 can include, for example, a touchscreen display, and can provide input options for configuring therapy. User interface 304 can also provide, for example, a graphical display of a blood flow rate or blood flow rate profile, as illustrated below in
Therapeutic subsystem 308 includes the hardware and software for providing the actual therapy. For example, therapeutic subsystem 308 can provide the pumps, filters, chemicals, pharmaceutical compounds, or other objects that are used to provide the therapy to the patient.
Hardware platform 312 can include the hardware for operating medical device 300. This could include, for example, a microcontroller, volatile and/or nonvolatile memory, interfaces, and other hardware elements. Hardware platform 312 can drive user interface 304, can control or interface with therapeutic subsystem 308, and can provide the platform for therapy software 316, AI engine 320, and recommendation engine 324.
Therapy software 316 can include software that interfaces with therapeutic subsystem 308 to provide therapy, to interface with sensors and other inputs, to collect user inputs via user interface 304, and to process results.
AI engine 320 includes an AI circuit which can be programmed to provide an artificial intelligence model. For example, AI engine 320 could include an ANN, a decision tree, or any other artificial intelligence engine or algorithm. By way of illustrative and nonlimiting example, AI engine 320 can provide an algorithm selected from a group including linear regression, logistic regression, linear discriminant analysis, decision tree, naïve Bayes, k-nearest neighbors, learning vector quantization, support vector machine, random forest, or deep neural network.
AI engine 320 may, in some examples, be a relatively limited AI circuit, and cannot provide all of the training or preprocessing that a full AI solution requires. Rather, AI engine 320 can receive a preprocessed or pre-trained model from an outside source, such as a cloud service, and can run that model based on localized inputs within medical device 300. Thus, much of the preprocessing can be provided in the cloud, where greater processing resources can be available. AI engine 320 can therefore be a relatively lightweight AI engine, and can perform only the processing necessary to make decisions in real-time, or near real-time, on medical device 300.
Recommendation engine 324 interfaces with user interface 304 and AI engine 320. Recommendation engine 324 can receive, via user interface 304, a request for a recommendation, such as when the user operates a quick assist button, or some other function. Recommendation engine 324 can also receive from AI engine 320 a recommendation, such as a recommended blood flow rate or blood flow rate profile. This can be provided to the user via user interface 304, and, in some embodiments, the user can be able to either accept or reject the recommendation.
Blood pressure monitoring sensor 330 can be used to monitor the patient's blood pressure in real-time, or near real-time, and to optionally compare that blood pressure to a threshold, to determine whether the patient's blood pressure is below a threshold with a safety margin, and/or below a danger threshold.
Thus, while there is an adequate knowledge base of individuals who understand hemodialysis therapy, and who have the experience to appropriately adjust parameters during sessions, the application and transition of this acquired knowledge can be a challenge. During in-center sessions, if there is a need to change programming parameters, an in-house nephrologist or experienced home therapy nurse can be consulted. But for the in-home care setting, the patient or caretaker may not even realize that a particular parameter requires a need to consult a professional. Thus, although 24-hour service support is available to put the patient in contact with a home therapy registered nurse (RN) or nephrologist, the patient may not even realize when these services are needed. Furthermore, even when the patient does realize that a consultation is required, the consultation can take a long time, requiring the patient to contact the 24-hour service, explain the issue, get potential solutions, and walk through the results.
Furthermore, for a nephrologist or RN to provide appropriate consultation, the professional may need to skim through the history of medical practice and EHRs for the patient to provide a prescription that is targeted to the patient's individual circumstances. The prescription may vary based on the experience level of the professional, as the professional may lack a generic tool to view treatment parameter recommendations.
Embodiments of this specification achieve benefits by suggesting and/or automating treatment parameters such as blood flow rate and profiles, and can optionally provide a visual representation of the blood flow rate during hemodialysis. This can be observed by both patients and attending nurses during hemodialysis delivery and blood return.
For many individuals, the effectiveness of dialysis treatment is dependent on the blood flow. Thus, the present specification uses a blood flow rate recommendation for dialysis treatment as an illustrative example of the principles taught herein. One of skill will understand that the dialysis machines disclosed herein could be replaced by any other biomedical device, or by any other device that could benefit from the teachings of this specification. Furthermore, blood flow rate could be replaced by any other treatment parameter that influences dialysis clearance, or by some other therapeutic factor for dialysis, or a different therapy. Furthermore, examples of the present specification are disclosed in terms of hemodialysis home therapy methods that are performed by patients or attended by registered nurses in the home. However, the teachings of this specification can also benefit physicians or other professionals who desire an aid for their own analysis. Embodiments disclosed herein recommend and automate blood flow rate using a therapy or smart engine with an AI assistance.
In one illustrative example, a cloud-based analysis module performs initial analysis on a number of parameters, and then provides a pre-trained AI model that can be deployed on an individual system. This pre-trained model can then be distributed, for example, via a secure network connection to an individual device that is performing in-home treatment. The individual device receives the pre-trained AI model, and runs the model in its own AI circuit. During treatment, the user can request a recommendation, such as a recommended blood flow profile, or the system can detect that the blood flow has an issue. For example, the blood flow rate can be too low to provide the desired therapy results, or a blood pressure sensor could indicate that the patient's blood pressure has dropped below a threshold, and thus, the blood flow rate should be decreased for the patient's health and safety.
Advantageously, by dividing the logic between two devices, the “heavy lifting” of the computations, such as parsing large volumes of data and training a model, can be performed on the backend in the cloud, where more processing power can be available. On the front end, at the dialysis machine, the pre-trained model can be run on the AI circuit, utilizing relatively fewer system resources. Although this split between workloads is illustrated as an example in this specification, one of skill will understand that any of the examples shown below, including the examples that explicitly show such a split, could also be applied to a system where all the processing occurs on a single device.
The analytical system disclosed herein uses a combination of analytical data obtained from various lab testing and history data for treatment parameters to identify and recommend a suggested blood flow rate for a patient, which can be delivered at each phase of a hemodialysis treatment delivery. Treatment parameters can include, by way of illustrative and nonlimiting example, patient access type, dialyzer type, therapy method, patient conditions, fluid removal, dialyzer permeability, patient weight, patient dry weight (e.g., a patient's weight before treatment), treatment time, treatment goals, or others. The system disclosed can provide multiple treatment parameter profile suggestions. This can allow the user to choose between a number of recommended ranges.
Furthermore, the system can suggest a recommended blood flow rate in the event of an adverse common condition during the treatment session. The patient or nurse can choose to accept or override a recommendation. For example, an adverse condition could include an unsafe drop in blood pressure. In that case, the system can suggest a change to the treatment parameters, such as the blood flow rate. The user can choose to accept or reject this recommendation, although in some embodiments, if the blood pressure or other parameter drops below an important threshold, the user selection can be overridden to protect the patient's life, health, or safety.
In at least some embodiments, the system suggests or automates the blood flow rate settings upon a user consensus, and/or in the event of adverse conditions, such as for low patient blood pressure. The system can also suggest or automate blood flow rates for common conditions that require changes in blood flow rate during hemodialysis delivery and blood return. In some cases, if the blood flow rate is changed (i.e., increased or decreased) during the treatment session, the system can dynamically predict a recommendation based on the changed blood flow rate, and provide that recommendation in real-time, or near real-time.
In further embodiments, the system can save the recommended blood flow rate profiles for a patient on the hemodialysis machine, or on a patient access card that is used to access and control the hemodialysis machine. This can include saving blood flow rate profiles for a home hemodialysis patient, or for in-clinic hemodialysis use.
Notably, although blood flow rate has been illustrated herein as an example parameter, the system can also be used to adjust other parameters, such as sodium profiles, ultrafiltration rate profiles, and other profiles that can influence dialysis adequacy.
may be surprised to learn that the reading material and the training do not translate directly into handling real-world issues during real treatment sessions. Issues could range from incorrect consumable installation, incorrect treatment parameter programming, incorrect medication, obstruction in the extracorporeal blood tube, incorrect handling of pressure alarms, and errors in treatment delivery.
Smart Therapy Analysis Module
As discussed above, a smart therapy analysis module is a software module that optionally can be hosted in the cloud. The smart therapy analysis module can be used to pre-train an AI model that can be executed on the home dialysis machine. This software can be provided with inputs that include analytical data. The analytical data can be obtained by lab regression testing of various treatment parameters, physiological parameters, adverse condition combinations, and the resultant clinical output. The treatment parameters could include, by way of illustrative and nonlimiting example, prescribed blood flow rate, treatment time, treatment goal, fluid to be removed, patient conditions, dialyzer type used, vascular access type, patient age, patient gender, patient physiological condition, patient treatment logs, or others. The clinical output data might include urea removed ratio/percentage and Kt/V over a time period.
The smart therapy software module can be used to analyze these factors, and provide a pre-trained AI model, or other inputs that can be used to control an AI model, which can be executed on the home therapy machine.
Artificial Intelligence Module
The home dialysis machine can include an AI module. The input for the AI module can include the data analytics from the smart therapy analysis module discussed above, which can be retrieved via a secure internet connection. Other inputs can include current treatment parameters entered on the user interface (UI), or parameters obtained in a safe and encrypted form from a cloud-based EHR repository. The AI circuit can compare the smart therapy and the current EHR data to provide a recommended high clearance prediction, and a recommended range of treatment parameters. The predictions and recommendations can be gathered using a basic machine learning regression model, or some other machine learning model. The regression model can identify patterns, relationships between different combinations of data, or other relationships. During a new treatment session, the model can suggest appropriate treatment parameters for high clearance and overall clinical output of the session. In some cases, current EHR details entered on the UI can be compared to lab result data analytics, to provide important treatment parameter adjustments for higher clearance.
The patient's blood sample may be measured to determine whether the dialysis has removed enough waste product from the blood. The patient's blood sample may be measured for dialysis adequacy periodically, including before dialysis starts, a month after dialysis is started, or twice a month during dialysis, by way of nonlimiting example. Factors that may be computed from these measurements include a urea reduction ratio (URR), and a clearance per treatment over water volume t. These are calculated from the patient's blood sample to assess the dialysis adequacy. Based on these values, a physician may update the treatment parameters to improve dialysis adequacy. To improve dialysis clearance K, the physician may attempt to optimize the rate at which blood flows through the dialyzer, referred to as the “blood flow rate.” If the blood flow is optimal, then the dialysis clearance rate is improved. However, the blood flow rate cannot be increased indiscriminately. Changing the blood flow rate may depend on factors including the maturity and strength of the patient's vascular access. The clearance may be adjusted by choosing the correct treatment parameters, such as dialyzer type, treatment time, treatment goal, patient's weight, patient conditions, and similar. Blood flow rate is a primary treatment parameter for the dialysis efficiency and efficacy. Fluctuations in the blood flow rate during the dialysis influence the dialysis clearance and the health of vascular access.
In some cases, in-center treatments are performed on average three times per week, usually for about four hours per session. Home hemodialysis may also be performed, depending on the type of therapy chosen. Long home therapy sessions may be performed three times a week (e.g., for four hours). Short treatments may be done five to six days a week, with shorter treatment times between three and four hours. Nocturnal treatments may be performed daily while the patient is asleep, for approximately six to seven hours.
Nurses can sign up for home therapy RN courses. A home therapy RN course could last for as many as six months. Home therapy nurses can also train home dialysis patients for home hemodialysis. However, as in the previous case, theory and training do not always translate directly to real-world issues, particularly for relatively new nurses. This can increase difficultly for the nurse to do his or her job, and also impact the nurse's ability to train home care patients. Often, nurses may meet different sets of patients with different adverse conditions. Nurses need to be able to adjust treatment parameters according to situations that arise during individual sessions. The nurse needs to handle real-time scenarios in a clinically appropriate fashion. Nurses may also be bombarded with questions from patients regarding programming and other parameters during the session.
The patient's blood may be monitored to determine whether the dialysis has removed enough waste product. A physician may update the treatment parameters to improve dialysis adequacy. However, the blood flow rate cannot be increased indiscriminately. Changing the blood flow rate may depend on factors including the maturity and strength of the patient's vascular access. The clearance may be adjusted by choosing the correct treatment parameters, such as dialyzer type, treatment time, treatment goal, patient's weight, patient conditions, and similar.
User Interface
In an embodiment, the recommended blood flow rate for improved dialysis clearance can be displayed and recommended in the form of a graph on the UI. Once the patient or home therapy nurse confirms the prescription treatment parameters from the EHR on the UI, the values can be predicted by the AI circuit disclosed above. In one example, the UI includes a “smart assist” UI button to display the recommendations on the UI. The treatment parameter prediction (e.g., blood flow rate) can be recommended on the UI during the entire treatment session. When data are displayed in a graphical form, in one embodiment, the highest point on the Y axis signifies the high blood flow rate. The highest point on the X axis signifies the treatment time. The system can display individual blood flow rate or a series of blood flow rates over the period of treatment. In the case of a plurality of blood flow rates, these can be saved as a blood flow rate profile.
In an embodiment, the patient or nurse can click on the blood flow rate points to accept a suggested value. The value can then be set in the treatment parameters, optionally with a double confirmation. The patient or nurse can also overwrite the blood flow rate suggestion with an edit option. For example, the patient can “drag” blood flow rate points to change the blood flow rate at a particular time in the course of treatment. If the patient is in doubt, the patient or nurse can check the profile, such as a stored profile, to decide on a course of treatment.
Advantageously, this reduces the cognitive load on the user. The system provides an option to save blood flow rate profiles for a patient on the hemodialysis device or a patient card. The saved profile in the patient card can be viewed or reviewed by a nephrologist or other doctor at the next appointment, and a prescription can be adjusted as necessary. This gives the nephrologist the ability to decide on the treatment parameters, without needing to skim through numerous data. The blood flow rate profiles or the recommended values might be logged for each treatment. These logs might be helpful in improving the AI model, and in some cases, results of treatment can be uploaded back to the cloud for further analysis by the smart software module. In some embodiments, these data are anonymized so that patient privacy is not compromised.
In the event of an adverse condition, a blood flow rate might be suggested to the user. Accepting this value during treatment can result in a dynamic suggestion or a change in blood flow rate instantaneously.
In an embodiment, the AI circuit can also have an interface to a voice-activated user prompt for patients with hearing and cognitive impairments. This can allow voice control to further ease patient operation.
Example User Interface Outputs
In the example of
As illustrated in
Cloud Service and Medical Device Interaction
Cloud service 601 includes a cloud hardware platform 602, that collects various data referred to herein as static data 615. Static data 615 are so labeled because they are relatively static compared to the real-time, or near real-time, treatment data, which can change continuously during the course of treatment. In contrast, the static data are not expected to change during the course of treatment. Static data can include, by way of illustrative and nonlimiting example, treatment goals, prescription parameters, dialyzer type, patient physiology, patient lab report data, and patient medical history. Static data 615 can also be combined with EHR 606, which can contain historical patient data. These can then be provided to analysis module 604. Analysis module 604 can analyze static data 615 and EHR data 606, along with any other data that can be provided, such as data that are more applicable to a general population or class of people. Analysis module 604 uses these to create a trained or otherwise prepared AI model 612. Trained AI model 612 is ready to be run on an endpoint device, such as a specific medical device. In this example, trained AI model 612 is specific to the individual patient and the treatment conditions.
Analytical data for trained AI model 612 may be obtained, for example, by lab regression testing of various treatment parameters, physiological parameters, and adverse condition combinations. The resultant clinical outputs may be based on various patient data and biochemically-fabricated samples. The treatment parameters may include, by way of illustrative and nonlimiting example, prescribed blood flow rate, treatment time, treatment goal, fluid to be removed, patient conditions, dialyzer types used, vascular access type, patient's age and gender, patient physiological conditions, and patient treatment logs. The clinical output data might include urea removed ratio/percentage and Kt/V over a period
The input for the AI engine may include data analytics from software control module 620, and current treatment parameters entered on the user interface, or alternatively obtained in safe encrypted form from a cloud-based EHR service and/or picture archiving and communication system (PACS).
The proposed AI may then compare the smart therapy and the current EHR data to provide optimal high clearance predictions and recommendations ranges for the treatment parameters.
For example, the AI system may compare current EHR details (entered on the UI or retrieved from a service) against laboratory results data analytics, and a learning regression model from history data. The result may be a recommendation for critical treatment parameter adjustment for high clearance. Hyperparameter tuning may occur as part of the learning regression model.
The AI model predictions and recommendations may be gathered, in at least one embodiment, by using a machine learning regression model. The regression model may identify patterns and relations between different combination of data.
During a new treatment session, AI circuit 616 of medical device 603 may suggest appropriate treatment parameters for high clearance and overall clinical output of the session.
Trained AI model 612 is provided to medical device 603, which uses AI circuit 616 to process trained AI model 612. AI circuit 616 receives sensor inputs 624, such as via smart sensors connected to the home (e.g., smart scales, smart BP monitors, smart pulse oximeters, or other smart sensors), as well as manual user inputs, as necessary. AI circuit 616 also receives analytical data 632. Together, these form the inputs to AI circuit 616, which provides recommendations to software control module 620. Software control module 620 provides inputs and outputs to GUI 628, which can provide the recommendation to a user, and can receive an indication of whether the user has accepted the recommendation. Software control module 620 can then control therapeutic subsystem 640.
Method (As Performed, for Example, by a Cloud Service)
The method starts in block 704.
In block 706, the system collects patient historical data and other inputs that can be used to train or refine a model.
In block 708, the system applies an AI algorithm to pre-train a patient-specific model.
In block 710, the system publishes the patient-specific model to an individual device, such as by transferring the model via a secure network connection to the individual device.
In block 712, the system can receive treatment results or feedback from the individual device. These can also be received via a secure network connection.
In block 716, the system can optionally incorporate the feedback into the patient-specific model, and/or into more general models applicable to other patients.
In block 720, the system can republish the patient-specific model to the individual device. This republished model can include the incorporated feedback, and optionally, improvements derived from other patient data. The process of improvement can then continue in a loop between blocks 712 and 720.
Method (as Performed, for Example, by an Individual Therapeutic Device)
Starting at block 804, in block 806 the system receives the patient-specific model from the cloud. For example, the system can operate a secure network connection to download the patient-specific model from a cloud service.
In block 808, the system runs the patient-specific model in a programmable circuit, such as an AI circuit.
In block 810, either autonomously or in response to a stimulus, such as the user pressing a smart assist button, the system provides a recommendation. The recommendation can include a suggested flow rate, or a suggested flow rate profile, by way of nonlimiting example.
In block 812, therapy commences. As therapy continues, the system can continuously monitor the patient to ensure that safety is maintained. For example, increasing the blood flow rate too high can help to increase clearance, but could cause the patient's blood pressure to drop dangerously low. Thus, in this example, a blood pressure sensor is used to monitor the patient's blood pressure. In other embodiments, other sensors could be used to monitor other parameters.
In decision block 816, if the blood pressure drops below a threshold, then control returns to block 808, where the system can use this new input to recalculate a recommended blood flow profile. The user can be given an opportunity to accept or reject this recommendation, unless the blood pressure drops dangerously low, in which case an automatic override can occur.
If the blood pressure remains above the threshold, then looping back to block 812, therapy continues until the therapy is complete.
In block 820, the therapy ends. For example, block 820 can represent the end of a 3-to-4-hour hemodialysis session.
In block 824, optionally, the patient's therapeutic results from this session can be uploaded back to the cloud service to help further improve the model. Note that for the purpose of improving a patient-specific model, the therapeutic results should be associated with the individual patient. However, one of skill will understand that the data can be aggregated from one or more patients to improve the general model. The data can be anonymized to preserve patient privacy.
In block 890, the method is done.
Network Function Virtualization (NFV) Infrastructure
NFV is an aspect of network virtualization that is generally considered distinct from, but that can still interoperate with, software-defined networking (SDN). For example, virtual network functions (VNFs) can operate within the data plane of an SDN deployment. NFV was originally envisioned as a method for providing reduced capital expenditure (Capex) and operating expenses (Opex) for telecommunication services.
One feature of NFV is replacing proprietary, special-purpose hardware appliances with virtual appliances running on commercial off-the-shelf (COTS) hardware within a virtualized environment. In addition to Capex and Opex savings, NFV provides a more agile and adaptable network. As network loads change, VNFs can be provisioned (“spun up”) or removed (“spun down”) to meet network demands. For example, in times of high load, more load balancing VNFs can be spun up to distribute traffic to more workload servers (which can themselves be virtual machines). In times when more suspicious traffic is experienced, additional firewalls or deep packet inspection (DPI) appliances can be needed.
Because NFV started out as a telecommunications feature, many NFV instances are focused on telecommunications. However, NFV is not limited to telecommunication services. In a broad sense, NFV includes one or more VNFs running within a network function virtualization infrastructure (NFVI), such as NFVI 900. Often, the VNFs are inline service functions that are separate from workload servers or other nodes. These VNFs can be chained together into a service chain, which can be defined by a virtual subnetwork, and which can include a serial string of network services that provide behind-the-scenes work, such as security, logging, billing, and similar.
In the example of
Note that NFV orchestrator 901 can be virtualized (rather than a special-purpose hardware appliance). NFV orchestrator 901 can be integrated within an existing SDN system, wherein an operations support system (OSS) manages the SDN. This can interact with cloud resource management systems (e.g., OpenStack) to provide NFV orchestration. An NFVI 900 can include the hardware, software, and other infrastructure to enable VNFs to run. This can include a hardware platform 902 on which one or more VMs 904 can run. For example, hardware platform 902-1 in this example runs VMs 904-1 and 904-2. Hardware platform 902-2 runs VMs 904-3 and 904-4. Each hardware platform can include one or more hypervisor 920-1, virtual machine manager (VMM), or similar function, which can include and run on a native (bare metal) operating system, which can be minimal so as to consume very few resources.
Hardware platforms 902-1 or 902-2 can be or comprise a rack or several racks of blade or slot servers (including, e.g., processors, memory, and storage), one or more data centers, other hardware resources distributed across one or more geographic locations, hardware switches, or network interfaces. An NFVI 900 can also include the software architecture that enables hypervisors to run and be managed by NFV orchestrator 901.
Running on NFVI 900 are a number of VMs 904, each of which in this example is a VNF providing a virtual service appliance. Each VM 904 in this example includes an instance of the Data Plane Development Kit (DPDK), a virtual operating system 908, and an application providing the VNF 912 including VNF-1912-1, VNF-2912-2, VNF-3912-3, VNF-4912-4. Any number of additional VNF can be provided, as required. The virtual operating system 908 can include Virtual OS 908-1, Virtual OS 908-2, Virtual OS 908-3, Virtual OS 908-4, or any number of additional virtual operating systems as required.
Virtualized network functions could include, as nonlimiting and illustrative examples, firewalls, intrusion detection systems, load balancers, routers, session border controllers, DPI services, network address translation (NAT) modules, or call security association.
The illustration of
The illustrated collective DPDK instances 916-1, 916-2, 916-3, and 916-4 provide a set of optimized libraries for communicating across a virtual switch (vSwitch) 922. DPDK 916-1 and DPDK 916-2 can be associated with hardware platform 902-1. DPDK 916-3 and DPDK 916-4 can be associated with hardware platform 902-2. Like VMs 904-3 and 904-4, switch 922 can be provisioned and allocated by a hypervisor 920-1. The hypervisor uses a network interface to connect the hardware platform to the data center fabric (e.g., a host fabric interface (HFI)). This HFI can be shared by all VMs 904-1, 904-2, 904-3, and 904-4 running on the hardware platform 902-1 or hardware platform 902-2. Thus, the vSwitch can be allocated to switch traffic between VMs 904. The vSwitch can be a pure software vSwitch (e.g., a shared memory vSwitch), which can be optimized so that data are not moved between memory locations, but rather, the data can stay in one place, and pointers can be passed between VMs 904 to simulate data moving between ingress and egress ports of the vSwitch. The vSwitch can also include a hardware driver (e.g., a hardware network interface intellectual property (IP) block that switches traffic, but that connects to virtual ports rather than physical ports). In this illustration, a distributed vSwitch 922 is illustrated, wherein vSwitch 922 is shared between two or more physical hardware platforms 902.
One skilled in the art will understand that various combinations and/or modifications and variations can be made in the described systems and methods depending upon the specific needs for operation. Various aspects disclosed herein can be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. Moreover, features illustrated or described as being part of an aspect of the disclosure can be used in the aspect of the disclosure, either alone or in combination, or follow a preferred arrangement of one or more of the described elements. Depending on the example, certain acts or events of any of the processes or methods described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., certain described acts or events cannot be necessary to carry out the techniques). In addition, while certain aspects of this disclosure are described as performed by a single module or unit for purposes of clarity, the techniques of this disclosure can be performed by a combination of units or modules associated with, for example, a device.
Number | Name | Date | Kind |
---|---|---|---|
3602222 | Herndon | Aug 1971 | A |
3608729 | Haselden | Sep 1971 | A |
3669878 | Marantz | Jun 1972 | A |
3669880 | Marantz | Jun 1972 | A |
3730183 | Goldsmith | May 1973 | A |
3754867 | Guenther | Aug 1973 | A |
3850835 | Marantz | Nov 1974 | A |
3884808 | Scott | May 1975 | A |
3989622 | Marantz | Nov 1976 | A |
3989625 | Mason | Nov 1976 | A |
4060485 | Eaton | Nov 1977 | A |
4371385 | Johnson | Feb 1983 | A |
4374382 | Markowitz | Feb 1983 | A |
4381999 | Boucher | May 1983 | A |
4460555 | Thompson | Jul 1984 | A |
4556063 | Thompson | Dec 1985 | A |
4562751 | Nason | Jan 1986 | A |
4581141 | Ash | Apr 1986 | A |
4650587 | Polak | Mar 1987 | A |
4661246 | Ash | Apr 1987 | A |
4678408 | Mason | Jul 1987 | A |
4685903 | Cable | Aug 1987 | A |
4747822 | Peabody | May 1988 | A |
4750494 | King | Jun 1988 | A |
4772560 | Attar | Sep 1988 | A |
4799493 | DuFault | Jan 1989 | A |
4826663 | Alberti | May 1989 | A |
4828693 | Lindsay | May 1989 | A |
4976683 | Gauthier | Dec 1990 | A |
5032265 | Jha | Jul 1991 | A |
5080653 | Voss | Jan 1992 | A |
5091642 | Chow | Feb 1992 | A |
5092838 | Faict | Mar 1992 | A |
5092886 | Dobos-Hardy | Mar 1992 | A |
5097122 | Coiman | Mar 1992 | A |
5127404 | Wyborny | Jul 1992 | A |
5141493 | Jacobsen | Aug 1992 | A |
5284470 | Beltz | Feb 1994 | A |
5302288 | Meidl | Apr 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5318750 | Lascombes | Jun 1994 | A |
5364593 | Mihaylov | Nov 1994 | A |
5415838 | Rieger | May 1995 | A |
5468388 | Goddard | Nov 1995 | A |
5507723 | Keshaviah | Apr 1996 | A |
5643201 | Peabody | Jul 1997 | A |
5651893 | Kenley | Jul 1997 | A |
5683432 | Goedeke | Nov 1997 | A |
5744031 | Bene | Apr 1998 | A |
5762782 | Kenley | Jun 1998 | A |
5819007 | Elghazzawi | Oct 1998 | A |
5902336 | Mishkin | May 1999 | A |
5944684 | Roberts | Aug 1999 | A |
5987352 | Klein | Nov 1999 | A |
6042721 | Peters | Mar 2000 | A |
6048732 | Anslyn | Apr 2000 | A |
6052622 | Holmstrom | Apr 2000 | A |
6058331 | King | May 2000 | A |
6156002 | Polaschegg | Dec 2000 | A |
6230059 | Duffin | May 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6254567 | Treu | Jul 2001 | B1 |
6321101 | Holmstrom | Nov 2001 | B1 |
6362591 | Moberg | Mar 2002 | B1 |
6363279 | Ben-Haim | Mar 2002 | B1 |
6505075 | Weiner | Jan 2003 | B1 |
6554798 | Mann | Apr 2003 | B1 |
6555986 | Moberg | Apr 2003 | B2 |
6589229 | Connelly | Jul 2003 | B1 |
6602399 | Fromherz | Aug 2003 | B1 |
6609023 | Fischell | Aug 2003 | B1 |
6627164 | Wong | Sep 2003 | B1 |
6645191 | Knerr | Nov 2003 | B1 |
6676608 | Keren | Jan 2004 | B1 |
6689083 | Gelfand | Feb 2004 | B1 |
6706007 | Gelfand | Mar 2004 | B2 |
6711439 | Bradley | Mar 2004 | B1 |
6726647 | Sternby | Apr 2004 | B1 |
6780322 | Bissler | Aug 2004 | B1 |
6818196 | Wong | Nov 2004 | B2 |
6878283 | Thompson | Apr 2005 | B2 |
6887214 | Levin | May 2005 | B1 |
6890315 | Levin | May 2005 | B1 |
6960179 | Gura | Nov 2005 | B2 |
7074332 | Summerton | Jul 2006 | B2 |
7077819 | Goldau | Jul 2006 | B1 |
7131956 | Pirazzoli | Nov 2006 | B1 |
7175809 | Gelfand | Feb 2007 | B2 |
7207946 | Sirokman | Apr 2007 | B2 |
7208092 | Micheli | Apr 2007 | B2 |
7276042 | Polaschegg | Oct 2007 | B2 |
7399289 | Gelfand | Jul 2008 | B2 |
7404799 | Koh | Jul 2008 | B1 |
7500958 | Asbrink | Mar 2009 | B2 |
7566432 | Wong | Jul 2009 | B2 |
7575564 | Childers | Aug 2009 | B2 |
7610086 | Ke | Oct 2009 | B1 |
7674231 | McCombie | Mar 2010 | B2 |
7704361 | Garde | Apr 2010 | B2 |
7736507 | Wong | Jun 2010 | B2 |
7744553 | Kelly | Jun 2010 | B2 |
7754852 | Burnett | Jul 2010 | B2 |
7756572 | Fard | Jul 2010 | B1 |
7775983 | Zhang | Aug 2010 | B2 |
7775986 | Roeher | Aug 2010 | B2 |
7776210 | Rosenbaum | Aug 2010 | B2 |
7785463 | Bissler | Aug 2010 | B2 |
7794141 | Perry | Sep 2010 | B2 |
7850635 | Polaschegg | Dec 2010 | B2 |
7857976 | Bissler | Dec 2010 | B2 |
7867214 | Childers | Jan 2011 | B2 |
7896831 | Sternby | Mar 2011 | B2 |
7922686 | Childers | Apr 2011 | B2 |
7922911 | Micheli | Apr 2011 | B2 |
7947179 | Rosenbaum | May 2011 | B2 |
7955291 | Sternby | Jun 2011 | B2 |
7967022 | Grant | Jun 2011 | B2 |
7981082 | Wang | Jul 2011 | B2 |
8000000 | Greenberg | Aug 2011 | B2 |
8034161 | Gura | Oct 2011 | B2 |
8070709 | Childers | Dec 2011 | B2 |
8096969 | Roberts | Jan 2012 | B2 |
8105260 | Tonelli | Jan 2012 | B2 |
8202503 | Putnam | Feb 2012 | B2 |
8183046 | Lu | May 2012 | B2 |
8187250 | Roberts | May 2012 | B2 |
8197439 | Wang | Jun 2012 | B2 |
8202241 | Karakama | Jun 2012 | B2 |
8246826 | Wilt | Aug 2012 | B2 |
8273049 | Demers | Sep 2012 | B2 |
8282828 | Wallenas | Oct 2012 | B2 |
8292594 | Tracey | Oct 2012 | B2 |
8313642 | Yu | Nov 2012 | B2 |
8317492 | Demers | Nov 2012 | B2 |
8357113 | Childers | Jan 2013 | B2 |
8366316 | Kamen | Feb 2013 | B2 |
8366655 | Kamen | Feb 2013 | B2 |
8404091 | Ding | Mar 2013 | B2 |
8409441 | Wilt | Apr 2013 | B2 |
8496809 | Roger | Jul 2013 | B2 |
8499780 | Wilt | Aug 2013 | B2 |
8500676 | Jansson | Aug 2013 | B2 |
8512271 | Moissl | Aug 2013 | B2 |
8518260 | Raimann | Aug 2013 | B2 |
8521482 | Akonur | Aug 2013 | B2 |
8535525 | Heyes | Sep 2013 | B2 |
8560510 | Brueggerhoff | Oct 2013 | B2 |
8580112 | Updyke | Nov 2013 | B2 |
8597227 | Childers | Dec 2013 | B2 |
8696626 | Kirsch | Apr 2014 | B2 |
8903492 | Soykan | Dec 2014 | B2 |
8926542 | Gerber | Jan 2015 | B2 |
9700663 | Burbank | Jul 2017 | B2 |
9907897 | Burbank | Mar 2018 | B2 |
10076599 | Eyrard | Sep 2018 | B2 |
10076735 | Jansson | Sep 2018 | B2 |
10173881 | Beavis | Jan 2019 | B2 |
10459459 | Beavis | Oct 2019 | B2 |
10478544 | Friederichs | Nov 2019 | B2 |
10610630 | Burbank | Apr 2020 | B2 |
20010048637 | Weigl | Dec 2001 | A1 |
20020016550 | Sweeney | Feb 2002 | A1 |
20020042561 | Schulman | Apr 2002 | A1 |
20020112609 | Wong | Aug 2002 | A1 |
20030028089 | Galley | Apr 2003 | A1 |
20030069481 | Hervy | Apr 2003 | A1 |
20030080059 | Peterson | May 2003 | A1 |
20030097086 | Gura | May 2003 | A1 |
20030105435 | Taylor | Jun 2003 | A1 |
20030113931 | Pan | Jun 2003 | A1 |
20030114787 | Gura | Jun 2003 | A1 |
20030187479 | TranThong | Oct 2003 | A1 |
20040019312 | Childers | Jan 2004 | A1 |
20040060865 | Callan | Apr 2004 | A1 |
20040068219 | Summerton | Apr 2004 | A1 |
20040099593 | DePaolis | May 2004 | A1 |
20040147900 | Polaschegg | Jul 2004 | A1 |
20040168969 | Sternby | Sep 2004 | A1 |
20040215090 | Erkkila | Oct 2004 | A1 |
20050065760 | Murtfeldt | Mar 2005 | A1 |
20050113796 | Taylor | May 2005 | A1 |
20050126961 | Bissler | Jun 2005 | A1 |
20050131331 | Kelly | Jun 2005 | A1 |
20050126998 | Childers | Jul 2005 | A1 |
20050150832 | Tsukamoto | Jul 2005 | A1 |
20050214863 | McDevitt | Sep 2005 | A1 |
20050234354 | Rowlandson | Oct 2005 | A1 |
20050234357 | Xue | Oct 2005 | A1 |
20050234381 | Niemetz | Oct 2005 | A1 |
20050234534 | Rowlandson | Oct 2005 | A1 |
20050236330 | Nier | Oct 2005 | A1 |
20050265895 | Kopelman | Dec 2005 | A1 |
20050274658 | Rosenbaum | Dec 2005 | A1 |
20060025661 | Sweeney | Feb 2006 | A1 |
20060025748 | Ye | Feb 2006 | A1 |
20060217771 | Soykan | Feb 2006 | A1 |
20060058731 | Burnett | Mar 2006 | A1 |
20060191850 | Bosetto | Aug 2006 | A1 |
20060195064 | Plahey | Aug 2006 | A1 |
20060226079 | Mori | Oct 2006 | A1 |
20060241709 | Soykan | Oct 2006 | A1 |
20060247548 | Sarkar | Nov 2006 | A1 |
20060264894 | Moberg | Nov 2006 | A1 |
20070007208 | Brugger | Jan 2007 | A1 |
20070031972 | Attar | Feb 2007 | A1 |
20070038138 | Gill | Feb 2007 | A1 |
20070066928 | Lannoy | Mar 2007 | A1 |
20070073168 | Zhang | Mar 2007 | A1 |
20070138011 | Hofmann | Jun 2007 | A1 |
20070161113 | Ash | Jul 2007 | A1 |
20070175827 | Wariar | Aug 2007 | A1 |
20070179431 | Roberts | Aug 2007 | A1 |
20070213653 | Childers | Sep 2007 | A1 |
20070215545 | Bissler | Sep 2007 | A1 |
20070222992 | Oda | Sep 2007 | A1 |
20070255250 | Moberg | Nov 2007 | A1 |
20070276270 | Tran | Nov 2007 | A1 |
20080006570 | Gura | Jan 2008 | A1 |
20080021337 | Li | Jan 2008 | A1 |
20080053905 | Brugger | Mar 2008 | A9 |
20080067132 | Ross | Mar 2008 | A1 |
20080093276 | Roger | Apr 2008 | A1 |
20080200866 | Prisco | Aug 2008 | A1 |
20080215247 | Tonelli | Sep 2008 | A1 |
20080233008 | Sarkisov | Sep 2008 | A1 |
20080253427 | Kamen | Oct 2008 | A1 |
20090020471 | Tsukamoto | Jan 2009 | A1 |
20090036825 | Petersen | Feb 2009 | A1 |
20090101577 | Fulkerson | Apr 2009 | A1 |
20090124869 | Hu | May 2009 | A1 |
20090124963 | Hogard | May 2009 | A1 |
20090127193 | Updyke | May 2009 | A1 |
20090149776 | Adams | Jun 2009 | A1 |
20090171261 | Sternby | Jul 2009 | A1 |
20090264776 | Vardy | Oct 2009 | A1 |
20090275849 | Stewart | Nov 2009 | A1 |
20090275883 | Chapman | Nov 2009 | A1 |
20090281484 | Childers | Nov 2009 | A1 |
20090282980 | Gura | Nov 2009 | A1 |
20090287467 | Sparks | Nov 2009 | A1 |
20090314063 | Sternby | Dec 2009 | A1 |
20100004588 | Yeh | Jan 2010 | A1 |
20100010425 | Yu | Jan 2010 | A1 |
20100010429 | Childers | Jan 2010 | A1 |
20100042035 | Moissl | Feb 2010 | A1 |
20100061892 | Flaim | Mar 2010 | A1 |
20100076398 | Scheurer | Mar 2010 | A1 |
20100078381 | Merchant | Apr 2010 | A1 |
20100078387 | Wong | Apr 2010 | A1 |
20100084330 | Wong | Apr 2010 | A1 |
20100087771 | Karakama | Apr 2010 | A1 |
20100094158 | Solem | Apr 2010 | A1 |
20100113891 | Barrett | May 2010 | A1 |
20100114012 | Sandford | May 2010 | A1 |
20100137693 | Porras | Jun 2010 | A1 |
20100137782 | Jansson | Jun 2010 | A1 |
20100168546 | Kamath | Jul 2010 | A1 |
20100217180 | Akonur | Aug 2010 | A1 |
20100217181 | Roberts | Aug 2010 | A1 |
20100224492 | Ding | Sep 2010 | A1 |
20100234795 | Wallenas | Sep 2010 | A1 |
20100241045 | Kelly | Sep 2010 | A1 |
20100264086 | Noack | Oct 2010 | A1 |
20100312172 | Hoffman | Dec 2010 | A1 |
20110017665 | Updyke | Jan 2011 | A1 |
20110048949 | Ding et al. | Mar 2011 | A1 |
20110066006 | Banet | Mar 2011 | A1 |
20110066043 | Banet | Mar 2011 | A1 |
20110071465 | Wang | Mar 2011 | A1 |
20110077574 | Sigg | Mar 2011 | A1 |
20110077575 | Kraemer | Mar 2011 | A1 |
20110079558 | Raimann | Apr 2011 | A1 |
20110081728 | Putnam | Apr 2011 | A1 |
20110087187 | Beck | Apr 2011 | A1 |
20110100909 | Stange | May 2011 | A1 |
20110106003 | Childers | May 2011 | A1 |
20110130666 | Dong | Jun 2011 | A1 |
20110137136 | Kotanko | Jun 2011 | A1 |
20110141116 | Dalesch | Jun 2011 | A1 |
20110144570 | Childers | Jun 2011 | A1 |
20110184340 | Tan | Jul 2011 | A1 |
20110208105 | Brandl | Aug 2011 | A1 |
20110272337 | Palmer | Nov 2011 | A1 |
20110301447 | Park | Dec 2011 | A1 |
20110301472 | Grober | Dec 2011 | A1 |
20120016228 | Kroh | Jan 2012 | A1 |
20120029937 | Neftel | Feb 2012 | A1 |
20120083729 | Childers | Apr 2012 | A1 |
20120085707 | Beiriger | Apr 2012 | A1 |
20120115248 | Ansyln | May 2012 | A1 |
20120135396 | McDevitt | May 2012 | A1 |
20120181230 | Kloeffel | Jul 2012 | A1 |
20120220528 | VanAntwerp | Aug 2012 | A1 |
20120258545 | Ash | Oct 2012 | A1 |
20120258546 | Marran | Oct 2012 | A1 |
20120259276 | Childers | Oct 2012 | A1 |
20120273354 | Soykan | Nov 2012 | A1 |
20120273415 | Gerber | Nov 2012 | A1 |
20120273420 | Gerber | Nov 2012 | A1 |
20120277546 | Soykan | Nov 2012 | A1 |
20120277551 | Gerber | Nov 2012 | A1 |
20120277552 | Gerber | Nov 2012 | A1 |
20120277604 | Gerber | Nov 2012 | A1 |
20120277650 | Gerber | Nov 2012 | A1 |
20120277655 | Gerber | Nov 2012 | A1 |
20120277722 | Gerber | Nov 2012 | A1 |
20120283581 | Olde et al. | Nov 2012 | A1 |
20120303079 | Mahajan | Nov 2012 | A1 |
20130037465 | Heyes | Feb 2013 | A1 |
20130062265 | Balschat | Mar 2013 | A1 |
20130116578 | QiAn | May 2013 | A1 |
20130168316 | Noguchi | Jul 2013 | A1 |
20130186759 | Lin | Jul 2013 | A1 |
20130193073 | Hogard | Aug 2013 | A1 |
20130199998 | Kelly | Aug 2013 | A1 |
20130211730 | Wolff | Aug 2013 | A1 |
20130213890 | Kelly | Aug 2013 | A1 |
20130228517 | Roger | Sep 2013 | A1 |
20130231607 | Roger | Sep 2013 | A1 |
20130248426 | Pouchoulin | Sep 2013 | A1 |
20130274642 | Soykan | Oct 2013 | A1 |
20130324915 | Britton | Dec 2013 | A1 |
20130330208 | Ly | Dec 2013 | A1 |
20130331774 | Farrell | Dec 2013 | A1 |
20140018727 | Burbank | Jan 2014 | A1 |
20140018728 | Plahey | Jan 2014 | A1 |
20140042092 | Akonur | Feb 2014 | A1 |
20140065950 | Mendelsohn | Mar 2014 | A1 |
20140088442 | Soykan | Mar 2014 | A1 |
20140110340 | White | Apr 2014 | A1 |
20140110341 | White | Apr 2014 | A1 |
20140158538 | Collier | Jun 2014 | A1 |
20140158588 | Pudil | Jun 2014 | A1 |
20140158623 | Pudil | Jun 2014 | A1 |
20140190876 | Meyer | Jul 2014 | A1 |
20140216250 | Meyer | Aug 2014 | A1 |
20140217028 | Pudil | Aug 2014 | A1 |
20140217029 | Meyer | Aug 2014 | A1 |
20140217030 | Meyer | Aug 2014 | A1 |
20140220699 | Pudil | Aug 2014 | A1 |
20140276100 | Satterfield | Sep 2014 | A1 |
20140314625 | Clift | Oct 2014 | A1 |
20150032023 | Soykan | Jan 2015 | A1 |
20150080682 | Gerber | Mar 2015 | A1 |
20150088047 | Gerber | Mar 2015 | A1 |
20150144539 | Pudil | May 2015 | A1 |
20150148697 | Burnes | May 2015 | A1 |
20150149096 | Soykan | May 2015 | A1 |
20150250427 | Soykan | Sep 2015 | A1 |
20150343126 | Merchant | Dec 2015 | A1 |
20150352269 | Gerber | Dec 2015 | A1 |
20150367054 | Gerber | Dec 2015 | A1 |
20160023467 | Smith | Feb 2016 | A1 |
20160143774 | Burnett | May 2016 | A1 |
20160166753 | Meyer | Jun 2016 | A1 |
20160206801 | Gerber | Jul 2016 | A1 |
20160331884 | Sigg | Nov 2016 | A1 |
20170319768 | Szpara | Nov 2017 | A1 |
20170364660 | Vigersky | Dec 2017 | A1 |
20180043080 | Gerber | Feb 2018 | A1 |
20180221555 | Rohde | Aug 2018 | A1 |
20190125952 | Jansson | May 2019 | A1 |
20190125954 | Mathiot | May 2019 | A1 |
20190151526 | Wieslander | May 2019 | A1 |
20190240389 | Rohde | Aug 2019 | A1 |
20200019823 | Wang | Jan 2020 | A1 |
20200282218 | McDonald | Sep 2020 | A1 |
20220031947 | Onesti | Feb 2022 | A1 |
20220051773 | Appelbaum | Feb 2022 | A1 |
Number | Date | Country |
---|---|---|
3149888 | Mar 2021 | CA |
1643368 | Jul 2005 | CN |
101193667 | Jun 2008 | CN |
101300476 | Nov 2008 | CN |
101400997 | Jan 2009 | CN |
101482572 | Jul 2009 | CN |
201342127 | Nov 2009 | CN |
101726465 | Jun 2010 | CN |
202048893 | Mar 2011 | CN |
103037917 | Apr 2013 | CN |
103180712 | Jun 2013 | CN |
103339503 | Oct 2013 | CN |
103394139 | Nov 2013 | CN |
103619372 | Mar 2014 | CN |
103751871 | Apr 2014 | CN |
103803479 | May 2014 | CN |
103901025 | Jul 2014 | CN |
104174077 | Dec 2014 | CN |
104685342 | Jun 2015 | CN |
104833635 | Aug 2015 | CN |
105008893 | Oct 2015 | CN |
105115921 | Dec 2015 | CN |
105142692 | Dec 2015 | CN |
105692957 | Jun 2016 | CN |
105928939 | Jul 2016 | CN |
106124491 | Nov 2016 | CN |
205672288 | Nov 2016 | CN |
107206147 | Sep 2017 | CN |
110415831 | Nov 2019 | CN |
101644667 | Feb 2020 | CN |
212619551 | Feb 2021 | CN |
3224823 | Jan 1984 | DE |
102006028172 | Dec 2017 | DE |
0266795 | Nov 1987 | EP |
0402505 | Dec 1990 | EP |
0272414 | Oct 1991 | EP |
0330892 | Jul 1994 | EP |
1175238 | Nov 2000 | EP |
1085295 | Nov 2001 | EP |
1281351 | Feb 2003 | EP |
2308526 | Oct 2003 | EP |
1364666 | Nov 2003 | EP |
1523347 | Jan 2004 | EP |
1523350 | Jan 2004 | EP |
0906768 | Feb 2004 | EP |
1691863 | Apr 2005 | EP |
2116269 | Feb 2008 | EP |
1450879 | Oct 2008 | EP |
1514562 | Apr 2009 | EP |
2219703 | May 2009 | EP |
1592494 | Jun 2009 | EP |
2398529 | Nov 2010 | EP |
2575827 | Dec 2010 | EP |
2100553 | Aug 2011 | EP |
2576453 | Dec 2011 | EP |
2701580 | Nov 2012 | EP |
2701595 | Nov 2012 | EP |
1345856 | Mar 2013 | EP |
2344220 | Apr 2013 | EP |
1351756 | Jul 2013 | EP |
2190498 | Jul 2013 | EP |
2701596 | Mar 2014 | EP |
1582226 | Jan 2016 | EP |
S55138462 | Oct 1980 | JP |
S63-143077 | Nov 1987 | JP |
2002533170 | Oct 2002 | JP |
2002542900 | Dec 2002 | JP |
2003235965 | Aug 2003 | JP |
2005-533573 | Nov 2005 | JP |
5-99464 | Oct 2012 | JP |
20010109443 | Dec 2001 | KR |
WO1992005814 | Apr 1992 | WO |
1995003839 | Feb 1995 | WO |
WO 1998054563 | Dec 1998 | WO |
WO1999006082 | Feb 1999 | WO |
9937342 | Jul 1999 | WO |
PCT1124599 | May 2000 | WO |
0057935 | Oct 2000 | WO |
WO2000057935 | Oct 2000 | WO |
2000066197 | Nov 2000 | WO |
200170307 | Sep 2001 | WO |
2001085295 | Sep 2001 | WO |
0185295 | Nov 2001 | WO |
2002013691 | Feb 2002 | WO |
WO 20020053211 | Jul 2002 | WO |
2003043677 | May 2003 | WO |
2003043680 | May 2003 | WO |
2003051422 | Jun 2003 | WO |
2004008826 | Jan 2004 | WO |
2004009156 | Jan 2004 | WO |
2004009158 | Jan 2004 | WO |
2004030716 | Apr 2004 | WO |
2004030717 | Apr 2004 | WO |
2004064616 | Aug 2004 | WO |
2005033701 | Apr 2005 | WO |
2005061026 | Jul 2005 | WO |
2005123230 | Dec 2005 | WO |
2006011009 | Feb 2006 | WO |
2006017446 | Feb 2006 | WO |
2007038347 | Apr 2007 | WO |
2007089855 | Aug 2007 | WO |
20070115321 | Oct 2007 | WO |
WO2009094035 | Jan 2008 | WO |
2008037410 | Apr 2008 | WO |
2009026603 | Dec 2008 | WO |
2009024566 | Feb 2009 | WO |
2009026603 | Mar 2009 | WO |
2009061608 | May 2009 | WO |
2009094184 | Jul 2009 | WO |
2009157877 | Dec 2009 | WO |
2009157878 | Dec 2009 | WO |
WO2009154955 | Dec 2009 | WO |
WO 20090154955 | Dec 2009 | WO |
2010024963 | Mar 2010 | WO |
2010028860 | Mar 2010 | WO |
2010033314 | Mar 2010 | WO |
2010033699 | Mar 2010 | WO |
2010077851 | Jul 2010 | WO |
2010096659 | Oct 2010 | WO |
2010121820 | Oct 2010 | WO |
2011025705 | Mar 2011 | WO |
2011026645 | Mar 2011 | WO |
WO2013022760 | Aug 2011 | WO |
WO 2011132046 | Oct 2011 | WO |
2011137693 | Nov 2011 | WO |
WO2011161056 | Dec 2011 | WO |
2012042323 | Apr 2012 | WO |
2012050781 | Apr 2012 | WO |
2012051996 | Apr 2012 | WO |
2012073420 | Jul 2012 | WO |
WO 2012129501 | Sep 2012 | WO |
2012148781 | Nov 2012 | WO |
2012148784 | Nov 2012 | WO |
2012148786 | Nov 2012 | WO |
2012148787 | Nov 2012 | WO |
2012148789 | Nov 2012 | WO |
2012162515 | Nov 2012 | WO |
WO2012148788 | Nov 2012 | WO |
WO 20120148784 | Nov 2012 | WO |
2012172398 | Dec 2012 | WO |
2013019179 | Feb 2013 | WO |
2013019994 | Feb 2013 | WO |
2013025844 | Feb 2013 | WO |
2013028809 | Feb 2013 | WO |
2013101292 | Jul 2013 | WO |
2013103607 | Jul 2013 | WO |
2013103906 | Jul 2013 | WO |
2013110906 | Aug 2013 | WO |
2013110919 | Aug 2013 | WO |
2013114063 | Aug 2013 | WO |
2013121162 | Aug 2013 | WO |
2013140346 | Sep 2013 | WO |
2013141896 | Sep 2013 | WO |
14066254 | May 2014 | WO |
14066255 | May 2014 | WO |
14077082 | May 2014 | WO |
2014121162 | Aug 2014 | WO |
2014121163 | Aug 2014 | WO |
2014121167 | Aug 2014 | WO |
2014121169 | Aug 2014 | WO |
WO2014121161 | Aug 2014 | WO |
WO 20140121161 | Aug 2014 | WO |
WO 20140121169 | Aug 2014 | WO |
WO2015081221 | Jun 2015 | WO |
WO 20150130205 | Sep 2015 | WO |
WO 20150159280 | Oct 2015 | WO |
WO 20160080883 | May 2016 | WO |
WO 20170034452 | Mar 2017 | WO |
WO 2017176687 | Oct 2017 | WO |
Entry |
---|
Heiko Hickstein, Et Al; “Clinical application of fuzzy-controlled blood pressure stabilization in patients prone to hypotension duirng hemodiaylsis”, Dyalysis & Transplantation, vol. 38, No. 2, Feb. 1, 2009, pp. 58-64. |
Henderson, et al, “Online Preparation of Sterile Pyrogen-Free Electrolyte Solution,” Trans. Am. Soc. Artif. Intern.Organs, 1978 pp. 465-467. |
Indian OA of Nov. 21, 2019 in 2981/KOLNP/2013. |
Indian Office Action for Application 201714030219, dated May 31, 2021. |
International Preliminary Report on Patentability for App. No. PCT/US2019/019334, dated Jun. 12, 2019. |
Laurent, Jeanpierre, “Continuous Monitoring of Dynamic Systems: Application to Monitoring of Dialyzed Patients” Oct. 30, 2004, received from internet: http://laurent.jeanpierre1.free.fr/recherche/papiers/aista2004.pdf. |
Office Action for Chinese Application No. 201710779349.3, dated Oct. 9, 2019. |
Office Action for European App. No. 17190066.5, dated Mar. 7, 2019. |
Office Action for European App. No. 17718241.7, dated Apr. 2, 2020. |
Office Action in Chinese App. No. 201710778666.3 dated Sep. 19, 2019. |
Office Action in Chinese App. No. 201780019238.0, dated Sep. 25, 2020. |
PCT/US2016/058579 International Search Report dated Jan. 31, 2017. |
PCT/US2016/058579 Written Opinion dated Jan. 31, 2017. |
PCT/US2017/025868 International Search Report dated Jun. 29, 2017. |
PCT/US2017/025868 Written Opinion dated Jun. 29, 2017. |
PCT/US2017/030377 International Search Report dated Sep. 1, 2017. |
PCT/US2017/030377 Written Opinion dated Sep. 1, 2017. |
PCTUS20170146199 ISR and written opinion, Feb. 19, 2018. |
PCTUS2017025858 International Search Report dated Jun. 29, 2017. |
PCTUS2017025858 Written Opinion dated Jun. 29, 2017. |
PCTUS2017025876 International Search Report dated Jun. 29, 2017. |
PCTUS2017025876 Written Opinion dated Jun. 29, 2017. |
Schmitt, et al, “Colorimetric Gas Sensing with Enhanced Sensitivity,” Procedia Engineering, vol. 168, Sep. 3, 2016, pp. 1237-1240. |
Second Chinese Office Action for Application No. 201811107614.4, dated Apr. 15, 2021. |
Wollenstein, et al, “Colorimetric gas sensors for the detection of ammonia, nitrogen dioxide, and carbon monoxide: current status and research trends”, Sensor and Test Conference 2011, Jan. 2, 2011, pp. 562-567. |
Written Opinion in Dutch App. No. 2018577, dated Nov. 2, 2017. |
€œ Resources, environment and sustainable development of agriculture,â€⋅ edited by Liu Zhaopu, China Agricultural Science and Technology Press, pp. 209-211, Aug. 31, 1994. |
€œ Rural Medical and Health Handbook, â€⋅ written by Shanghai “Rural Medical and Health Handbook Writing team, Shanghai Science and Technology Press, Jun. 1968, p. 435. |
€œSurface water environmental quality standard non-ionic ammonia conversion method, â€⋅ Teng Enjiang, et al, “China Environmental Monitoring, â€⋅ vol. 11, No. 4, pp. 7-9, Dec. 31, 1995. |
Brynda, et al., The detection of toman 2-microglcbuiin by grating coupler immunosensor with three dimensional antibody networks. Biosensors & Bioelectronics, 1999, 363-368, 14(4). |
Wheaton, et al., Dowex Ion Exchange Resins-Fundamentals of Ion Exchange; Jun. 2000, pp. 1-9. http://www.dow.com/scripts/litorder.asp?filepath=liquidseps/pdfs/noreg/177-01837.pdf. |
Zhong, et. al., Miniature urea sensor based on H(+)-ion sensitive field effect transistor and its application in clinical analysis, Chin. J. Biotechnol., 1992, 57-65. 8(1). |
PCT/US2012/034331, International Search Report and Written Opinion dated Jul. 9, 2012. |
Roberts M, The regenerative dialysis (REDY) sorbent system. Nephrology, 1998, 275-278:4. |
Hemametrics, Crit-Line Hematocrit Accuracy, 2003, 1-5, vol. 1, Tech Note No. 11 (Rev. D). |
Weissman, S., et al., Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin. Infec. Dis, (Jul. 29, 1999): 223-224. |
PCT/US2012/034334, International Search Report, Jul. 6, 2012. |
PCT/US2012/034335, International Search Report, Sep. 5, 2012. |
PCT/US/2012/034327, International Search Report, Aug. 13, 2013. |
PCT/US/2012/034329, International Search Report, Dec. 3, 2012. |
Foley, et al., Long Interdialytic Interval and Martality among Patients Receiving Hemodialysis, N Engl Jrnl Med. 2011:365(12):1099-1107. |
PCT International Search Report from International Application No. PCT/US2014/067650, dated Mar. 9, 2015. |
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-10G: Suppl. |
PCT/US2014/067650 International Search Report Written Opinion mailed Mar. 9, 2015. |
Bleyer, et al., Kidney International. Jun. 2006; 69(12):2268-2273. |
Bleyer, et. al., Sudden and cardiac death rated in hemodialysis patients, Kidney International. 1999, 1553-1559: 55. |
PCT/US2012/034335, International Preliminary Report on Patentability, Oct. 29, 2013. |
PCT/US2012/034303, Internationa Search Report, Jul. 6, 2013. |
PCT/US2012/034332, Internatonal Preliminary Report on Patentability, Oct. 29, 2013. |
PCT/US2012/034333, International Preliminary Report on Patentability, Oct. 29, 2013. |
PCT/US2012/034333, International Search Report, Aug. 29, 2012. |
PCT/US2012/034327, International Preliminary Report on Patentability, Oct. 29, 2013. |
PCT/US2012/034330, International Preliminary Report on Patentability, Oct. 29, 2013. |
Culleton, BF et al. Effect of Frequent Nocturnal Hemodialysis vs. Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. 2007 Journal of the American Medical Association 298 (11), 1291-1299. |
Redfield, et. al., Restoration of renal response to atria! natriuretic factor in experimental low-output heat failure, Am. J. Physiol., Oct. 1, 1989, R917-923:257. |
Rogoza, et. al., Validation of A&D UA-767 device for the self-measurement of blood pressure, Blood Pressure Monitoring, 2000, 227-231, 5(4). |
PCT/US2012/034329, International Preliminary Report on Patentability, Oct. 29, 2013. |
Lima, et. al., An electrochemical sensor based on nanostructure hollandite-type manganese oxide for detection of potassium ion, Sensors, Aug. 24, 2009, 6613-8625, 9. |
Maclean, et, al., Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat, J. App. Physiol., 1998, 1583-1592, 85(4). |
U.S. Appl. No. 13/757,693, dated Feb. 1, 2013. |
PCT/US2014/014357 International Search Report and Written Opinion dated May 19, 2014. |
PCT/US2014/014357 International Search Report and Written Opinion mailed May 19, 2014. |
Ronco et al. 2008, Cardiorenal Syndrome, Journal American College Cardiology, 52:1527-1539, Abstract. |
Overgaard, et. al., Activity-induced recovery of excitability in K+-depressed rat soleus muscle, Am. J. P 280: R48-R55, Jan. 1, 2001. |
Overgaard et. al., Relations between excitability and contractility in rate soleusmuscle: role of the NA+-K+ pump and NA+-K-S gradients. Journal of Physiology, 1999, 215-225, 518(1). |
Zoccali, Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD, Clinical Epidemiology, J. Am Soc Nephrol 24:639-646, 2013. |
Coast, et al. 1990, An approach to Cardiac Arrhythmia analysis Using Hidden Markov Models, IEEE Transactions On Biomedical Engineering. 1990, 37(9):826-835. |
Weiner, et al., Article: Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease, Book: Primer on Kidney Diseases (Author: Greenberg, et al.), 2009,499-505, 5th Ed., Saunders Elsevier, Philadelphia, PA. |
Velasco, Optimal Fluid Control can Normalize Cardiovascular Risk Markers and Limit Left Ventricular Hypertrophy in Thrice Weekly Dialysis Patients, Hemodialysis Intenational, 16:465-472, 2012. |
Whitman, CKD and Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapeutic Approaches, J Am Soc Nephrol, 23:1929-1939, 2012. |
Hall, Hospitalization for Congestive Heart Failure: United States, 2000-2010, NCHS Data Brief, No. 108, Oct. 2012. |
Albert, Fluid Management Strategies in Heart Failure, Critical Care Nurse, 32:20-32, 2012. |
PCT/US2014/065201 International Search Report mailed May 26, 2015. |
Genovesi, et al., Nephrology, Dialysis, Transplantation 2009; 24(8):2529-2536. |
Secemsky, et. al., High prevalence of cardiac autonomic dysfunction and T-wave alternans in dialysis patients. Heart Rhythm, Apr. 2011, 592-598 : vol. 8, No. 4. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 1-140. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 141-280. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 281-420. |
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 421-534. |
Wei, et. al., Fullerene-cryptand coated piezoelectric crystal urea sensor based on urease, Analytica Chimica Acta, 2001,77-85:437. |
Leifer et al., A Study on the Temperature Variation of Rise Velocity for Large Clean Bubbles, J. Atmospheric & Oceanic Tech., vol. 17, pp. 1392-1402, Oct. 2000. |
Talaia, Terminal Velocity of a Bubble Rise in a Liquid Column, World Acad. of Sci., Engineering & Tech., vol. 28, pp. 264-268, Published Jan. 1, 2007. |
The FHN Trial Group. In-Center. Hemodialysis Six Times per Week versus Three Times per Week, New England Journal of Medicine, 2010 Abstract. |
PCT/US2012/034332, International Search Report, Jul. 5, 2012. |
Siegenthaler, et al., Pulmonary fluid status monitoring with intrathoracic impedance, Journal of Clinical Monitoring and Computing, 24:449-451, published Jan. 12, 2011. |
John Wm Agar: Review: Understanding sorbent dialysis systems, Nephrology, vol. 15, No. 4, Jun. 1, 2010, pp. 406-411. |
European Office Action in Application 12717020.7 dated Sep. 14, 2016. |
Office Action in Chinese Application No. 201510511657.9 Dated Dec. 28, 2016. |
Lakerveld et al, Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: Design of a randomized controlled trial, 2008, BMC Endocrine Disorders, 8(6): 1-19. |
Gordhandas et al, Real-Time Extraction and Analysis of Key Morphological Features in the Electrocardiogram, for Data Compression and Clinical Decision Support, 2004, Computational Physiology, pp. 15-18. |
European Office Action in Application 12717020.7 dated Dec. 11, 2015. |
PCT/US2012/034331 International Preliminary Report on Patentability and Written Opinion dated Oct. 29, 2013. |
Office Action in Chinese Application No. 201280020932.1 Dated Jan. 7, 2015. |
Office Action in Chinese Application No. 201280020932.1 Dated Apr. 3, 2015. |
PCT/US2012/034330, International Search Report and Written Opinion dated Aug. 28, 2012. |
Office Action in Chinese Application No. 201280020937.4 dated Mar. 22, 2016. |
Office Action in Japanese Application No. 2014-508434 dated Nov. 16, 2015. |
Office Action in Japanese Application No. 2014-508434 dated Dec. 8, 2014. |
Office Action in Japanese Application No. 2014-508434 dated Nov. 4, 2016. |
Office Action in European Application No. 12717019.9 dated Feb. 16, 2017. |
Office Action in Chinese Application No. 201510511657.9 dated May 10, 2017. |
PCT/US2014/065201 International Preliminary Report on Patentability mailed May 19, 2016. |
Office Action in European Application No. EP 12717021.5 dated Feb. 3, 2017. |
Office Action in Chinese Application No. 201510593695.3 dated Jul. 12, 2017. |
Office Action in European Application No. EP 12719170.8 dated Jan. 14, 2015. |
Office Action in Japanese Application No. JP 2014-508437 dated Dec. 8, 2014. |
Nedelkov, et. al., Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry, Proteomics, 2002, 441-446, 2(4). |
European Search Report App 14865374.4, Jun. 12, 2017. |
European Search Report for Application No. 14865128.4 dated Jun. 20, 2017. |
Green et al., Sudden Cardiac Death in Hemodialysis Patients: an In-Depth Review , Am J Kidney Dis 57(6)921:929; published Apr. 18, 2011. |
Rajan et al. Generalized Feature Extraction for Time-Varying Autoregressive Models, IEEE Transacion Signal Processing vol. 44, No. 10; published Oct. 1, 1996. |
AU Examiners Report for Application No. 2017246829, dated Jan. 9, 2021. |
Australian Office Action for App. No. 2016349521, dated Aug. 31, 2020. |
Castellanos, et al., Clinical Relevance of Intraperitoneal Pressure in Peritoneal Dialysis Patients, Perit Dial Int. Sep.-Oct. 2017;37(5):562-567. doi: 10.3747/pdi.2016.00267. Epub Jul. 11, 2017. |
Chinese Office Action for App. No. 201710778666.3, dated Feb. 25, 2020. |
Chinese Office Action for App. No. 201710778666.3, dated Jul. 15, 2020. |
Chinese Office Action for App. No. 201710778666.3, dated Nov. 20, 2020. |
Chinese Office Action for App. No. 201710779349.3, dated Jun. 1, 2020. |
Chinese Office Action for App. No. 201710779964.4, dated Apr. 14, 2020. |
Chinese Office Action for App. No. 201710779964.4, dated Aug. 26, 2020. |
Chinese Office Action for App. No. 201780019237.6, dated Feb. 1, 2021. |
Chinese Office Action for App. No. 201780019237.6, dated May 25, 2020. |
Chinese Office Action for App. No. 201780019238.0, dated May 7, 2020. |
Chinese Office Action for App. No. 201780019362.7, dated Jun. 2, 2020. |
Chinese Office Action for App. No. 201810121459.5, dated Aug. 17, 2020. |
Chinese Office Action for App. No. 201810121459.5, dated Mar. 19, 2020. |
Chinese Office Action for App. No. 201811107614.4, dated Sep. 28, 2020. |
Chinese Office Action for App. No. 201811155891.2, dated Oct. 10, 2020. |
Chinese Office Action for App. No. 2019071601874110, dated Jul. 19, 2019. |
Chinese Office Action in App. No. 201480059332.5, Dated Mar. 30, 2018. |
Dejardin, et al, Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications, Nephrol Dial Transplant. May 2007;22(5):1437-44. |
European Office Action for App. No. 12719842.2, dated Jul. 15, 2020. |
European Office Action for App. No. 14859115.9, dated Mar. 25, 2020. |
European Office Action for App. No. 17190053.3, dated Sep. 18, 2019. |
European Office Action for App. No. 17718246.6, dated Apr. 2, 2020. |
European Office Action for App. No. 18204841.3, dated Aug. 20, 2020. |
European Office Action for App. No. 19173852.5, dated Aug. 28, 2020. |
European Search For App. No. 17190081.4, dated Feb. 5, 2021. |
European Search Report for App. No. 17185636.2, Dated Mar. 27, 2018. |
European Search Report for App. No. 14859115.9, dated Jan. 5, 2018. |
European Search Report for App. No. 17185636.2 dated Jan. 10, 2018. |
European Search Report for App. No. 17185638.8, dated Dec. 19, 2017. |
European Search Report for App. No. 17185808.7, dated Jan. 2, 2018. |
European Search Report for App. No. 17185810.3, dated Dec. 15, 2017. |
European Search Report for App. No. 17190053.3, dated Jan. 2, 2018. |
European Search Report for App. No. 17190066.5, dated Jan. 16, 2018. |
European Search Report for App. No. 17190081.4, dated Sep. 16, 2019. |
European Search Report for App. No. 17190084.8, dated Feb. 9, 2018. |
F. Locatelli, et al: “Haemodialysis with on-line monitoring equipment: tools or toys?” Nephrology Dialysis Transplantation., vol. 20, No. 1, Jan. 1, 2005. |
Number | Date | Country | |
---|---|---|---|
20230036006 A1 | Feb 2023 | US |